CN116234571A - 治疗视神经脊髓炎谱系障碍的方法 - Google Patents
治疗视神经脊髓炎谱系障碍的方法 Download PDFInfo
- Publication number
- CN116234571A CN116234571A CN202180046409.5A CN202180046409A CN116234571A CN 116234571 A CN116234571 A CN 116234571A CN 202180046409 A CN202180046409 A CN 202180046409A CN 116234571 A CN116234571 A CN 116234571A
- Authority
- CN
- China
- Prior art keywords
- subject
- nmosd
- need
- concentration
- sgfap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US63/046133 | 2020-06-30 | ||
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US63/052093 | 2020-07-15 | ||
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| US63/071092 | 2020-08-27 | ||
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116234571A true CN116234571A (zh) | 2023-06-06 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180046409.5A Pending CN116234571A (zh) | 2020-06-30 | 2021-06-30 | 治疗视神经脊髓炎谱系障碍的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172211A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534916A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230030642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178954A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299381A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006283A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180231571A1 (en) * | 2017-02-16 | 2018-08-16 | National Cancer Center | Biomarker for diagnosis of neuromyelitis optica or multiple sclerosis and use thereof |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3959241A4 (en) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE |
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
-
2021
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180231571A1 (en) * | 2017-02-16 | 2018-08-16 | National Cancer Center | Biomarker for diagnosis of neuromyelitis optica or multiple sclerosis and use thereof |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| CN111065413A (zh) * | 2018-05-25 | 2020-04-24 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| BRUCE A C CREE等: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial", THE LANCET, vol. 394, 5 September 2019 (2019-09-05), pages 3 - 4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022026747A2 (pt) | 2023-01-24 |
| WO2022006283A2 (en) | 2022-01-06 |
| MX2022016236A (es) | 2023-03-29 |
| CA3178954A1 (en) | 2022-01-06 |
| KR20230030642A (ko) | 2023-03-06 |
| EP4172211A4 (en) | 2024-07-10 |
| EP4172211A2 (en) | 2023-05-03 |
| US20230406928A1 (en) | 2023-12-21 |
| WO2022006283A3 (en) | 2022-02-03 |
| AU2021299307A1 (en) | 2022-12-22 |
| IL299381A (en) | 2023-02-01 |
| JP2023534916A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jeyakumar et al. | MOG antibody-associated optic neuritis | |
| Evoli et al. | Therapeutic options in ocular myasthenia gravis | |
| Akaishi et al. | Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica | |
| US20230406928A1 (en) | Methods of treating neuromyelitis optica spectrum disorder | |
| KR20220004113A (ko) | 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도 | |
| Jo et al. | Fever as a side effect after electroconvulsive therapy | |
| Kale | Management of optic neuritis as a clinically first event of multiple sclerosis | |
| Fox et al. | Thyroid eye disease: management, advances, and future opportunities | |
| US20230287114A1 (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| EP4426349A2 (en) | Methods for treating alzheimer's disease | |
| JP2023549075A5 (cg-RX-API-DMAC7.html) | ||
| Dai et al. | Rapid exacerbation of neuromyelitis optica after rituximab treatment | |
| HK40087593A (en) | Methods of treating neuromyelitis optica spectrum disorder | |
| TW202317181A (zh) | 治療視神經脊髓炎譜系障礙之方法 | |
| Kamijo et al. | Successful maintenance therapy with intravenous immunoglobulin to reduce relapse attacks and steroid dose in a patient with refractory myelin oligodendrocyte glycoprotein antibody-positive optic neuritis | |
| US20140234307A1 (en) | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis | |
| Kozińska et al. | Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD) | |
| Riboni Verri | Visual outcome measures of remyelination and neuroprotection in multiple sclerosis | |
| Dohlman et al. | Pivotal Trials in Ophthalmology | |
| Gilad et al. | Effect of time to initiation and dose of methylprednisolone on outcome in multiple sclerosis‐related optic neuritis | |
| HK40096777A (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| CN116583538A (zh) | 使用抗cd19抗体治疗自身免疫性疾病 | |
| Grzybowski et al. | Treatment of optic neuritis | |
| Sergeevna et al. | Neuromyelitis spectrum disorders | |
| Alemu et al. | Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40087593 Country of ref document: HK |